3. The impact of PCa on the European Society
Prostate cancer is the most common cancer in Europe for males
• Each year 417.000 men in Europe are diagnosed with prostate cancer
• 1 in 7 men in Europe will develop prostate cancer before the age of 85
• More than two million men living with prostate cancer
• 92.200 European men die of the disease every year
• The yearly costs of PCa in Europe is over 9 billion euros
5. The expectations
Health care burden of PCa is expected to
increase dramatically the coming years in
Europe:
• Ageing society will lead to higher
incidence and thus prevalence
• As a result the costs related to
PCa will increase significantly
Now is the time to raise greater awareness of Prostate Cancer in the EU!
Welcome everyone to the meeting and thank them for coming
In particular, I would like to thank the EU Commissioner for Health and Food Safety, Vytenis Andriukaitis for joining us and showing his support for this important issue
Say what the EAU does:
Guidelines, patient information, urology journal, education and training
EAU co-organised this event with our partners to promote the White Paper and to call for more action at EU level to tackle some of the challenges together.
Event aims to aaise awareness of the prevalence of the disease and how we can make improvements in the future.
Prevention > Awareness
Diagnosis > Standardised & Multidisciplinary
Treatment > Personalised & Equal level of care
Patient-centred, multidisciplinary approach
Equitable access to novel technology
Personalized medicine
Consistent Health Technology Assessment (HTA) should be performed for optimised allocation of resources
Awareness campaigns
Survivorship cancer plans
We need to collaborate to create a better future for all Europe’s PCa patients. Patients, clinicians, researchers must engage with all EU institutions.
This white paper wouldn’t be possible with the help of our partners. It’s clearly teamwork and the EAU would be happy to lead this transition in the future.